Bioatla Inc
NASDAQ:BCAB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.2667
1.22
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Bioatla Inc
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company is headquartered in San Diego, California and currently employs 56 full-time employees. The company went IPO on 2020-12-16. The Company’s product candidate includes BA3011 (Mecbotamab vedotin), BA3021 (Ozuriftabmab vedotin) and BA3071 (Ozuriftabmab vedotin). The Company’s lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL that is protein kinase receptor. BA3021 is developing a CAB antibody drug conjugate directed against receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is therapeutic for multiple solid tumor indications, including renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer and cervical cancer. The company has initiated a Phase I/II dose-escalation trial of BA3071 as monotherapy and in combination with an anti-PD-1 antibody with expansion cohorts to be enrolled upon identification of the recommended dose.
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company is headquartered in San Diego, California and currently employs 56 full-time employees. The company went IPO on 2020-12-16. The Company’s product candidate includes BA3011 (Mecbotamab vedotin), BA3021 (Ozuriftabmab vedotin) and BA3071 (Ozuriftabmab vedotin). The Company’s lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL that is protein kinase receptor. BA3021 is developing a CAB antibody drug conjugate directed against receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is therapeutic for multiple solid tumor indications, including renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer and cervical cancer. The company has initiated a Phase I/II dose-escalation trial of BA3071 as monotherapy and in combination with an anti-PD-1 antibody with expansion cohorts to be enrolled upon identification of the recommended dose.
Strategic Transaction: BioAtla is in advanced negotiations to finalize a strategic partnership by year-end.
FDA Alignment: FDA agreed to BioAtla's Phase III Oz-V trial design, enabling progress toward a registrational trial in second-line and later OPSCC.
Oz-V Opportunity: Oz-V targets a large, underserved cancer market, with estimated worldwide peak sales of $800 million in second-line OPSCC and a broader solid tumor opportunity exceeding $7 billion.
Promising Clinical Data: Oz-V showed a 45% response rate and 11.6 months median survival in Phase II, significantly better than current standard treatments.
Pipeline Progress: Encouraging safety and efficacy data reported for Dual-CAB EpCAM TCE and Mec-V programs, with key readouts expected in the first half of next year.
Reduced Expenses: R&D and G&A expenses decreased due to program prioritization and workforce reductions, with further R&D expense declines expected.
Financials: Cash at $8.3 million as of September 30, 2025, not including a recent $2 million milestone payment from Context Therapeutics.
